MedWatch

New product will positively impact sales prognosis, says CEO at GN Hearing

The delayed hybrid product Jabra Enhance Plus will finally hit the shelves in the US later this month, and the launch will affect sales projections for the better, CEO Gitte Aabo says ahead of the company’s 2022 guidance on Thursday.

Gitte Aabo, CEO of GN Hearing | Photo: BUNDGAARD CARSTEN/ERH

It was with great relief that GN Hearing’s management could unveil the launch of Jabra Enhance Plus, the company’s hybrid between a true wireless earbud and a hearing aid, on Tuesday. The rollout begins on February 25 in the US.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs